Ocular Therapeutix Inc.

7.35-0.0700-0.94%Vol 853.70K1Y Perf 42.75%
Jul 13th, 2020 16:00 DELAYED
BID7.07 ASK7.69
Open7.54 Previous Close7.42
Pre-Market- After-Market7.30
 - -%  -0.05 -0.68%
Target Price
9.33 
Analyst Rating
Strong Buy 1.00
Potential %
26.94 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
     36.62
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap392.23M 
Earnings Rating
Sell
Price Range Ratio 52W %
72.12 
Earnings Date
5th Aug 2020

Today's Price Range

7.337.72

52W Range

2.469.24

Summary:

Neutral

Technical Indicators: Sell
Moving Averages: Buy
Performance
1 Week
-2.13%
1 Month
-1.34%
3 Months
31.25%
6 Months
64.80%
1 Year
42.75%
3 Years
16.11%
5 Years
-70.34%
10 Years
-

TickerPriceChg.Chg.%
OCUL7.35-0.0700-0.94
AAPL381.91-1.7700-0.46
GOOG1 511.340.35000.02
MSFT207.07-6.6000-3.09
XOM42.660.01000.02
WFC25.41-0.0600-0.24
JNJ145.212.84001.99
FB239.00-6.0700-2.48
GE6.700.01000.15
JPM97.651.38001.43
Financial StrengthValueIndustryS&P 500US Markets
4.60
5.00
0.84
5.17
-12.50
Leverage Ratio -10.60
ProfitabilityValueIndustryS&P 500US Markets
52.50
-1 324.80
-1 285.60
-2 598.80
-
RevenueValueIndustryS&P 500US Markets
5.69M
0.09
32.52
19.66
Earnings HistoryEstimateReportedSurprise %
Q01 2020-0.40-0.41-2.50
Q04 2019-0.42-0.47-11.90
Q03 2019-0.46-0.452.17
Q02 2019-0.42-0.57-35.71
Q01 2019-0.42-0.45-7.14
Q04 2018-0.37-0.42-13.51
Q03 2018-0.36-0.38-5.56
Q02 2018-0.37-0.370.00
Earnings Per EndEstimateRevision %Trend
6/2020 QR-0.33-3.13Negative
9/2020 QR-0.27-8.00Negative
12/2020 FY-1.1011.29Positive
12/2021 FY-0.3528.57Positive
Next Report Date5th Aug 2020
Estimated EPS Next Report-0.33
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume853.70K
Shares Outstanding53.36M
Trades Count5.21K
Dollar Volume6.62M
Avg. Volume961.14K
Avg. Weekly Volume528.10K
Avg. Monthly Volume979.53K
Avg. Quarterly Volume965.08K

Ocular Therapeutix Inc. (NASDAQ: OCUL) stock closed at 7.36 per share at the end of the most recent trading day (a -0.94% change compared to the prior day closing price) with a volume of 854.98K shares and market capitalization of 392.23M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 167 people. Ocular Therapeutix Inc. CEO is Antony C. Mattessich.

The one-year performance of Ocular Therapeutix Inc. stock is 42.75%, while year-to-date (YTD) performance is 86.08%. OCUL stock has a five-year performance of -70.34%. Its 52-week range is between 2.46 and 9.24, which gives OCUL stock a 52-week price range ratio of 72.12%

Ocular Therapeutix Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 20.96, a price-to-sale (PS) ratio of 81.08, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -104.11%, a ROC of -129.34% and a ROE of -1 211.02%. The company’s profit margin is -%, its EBITDA margin is -1 285.60%, and its revenue ttm is $5.69 Million , which makes it $0.09 revenue per share.

Of the last four earnings reports from Ocular Therapeutix Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.33 for the next earnings report. Ocular Therapeutix Inc.’s next earnings report date is 05th Aug 2020.

The consensus rating of Wall Street analysts for Ocular Therapeutix Inc. is Strong Buy (1), with a target price of $9.33, which is +26.94% compared to the current price. The earnings rating for Ocular Therapeutix Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Ocular Therapeutix Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Ocular Therapeutix Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 24.76, ATR14 : 0.51, CCI20 : -107.11, Chaikin Money Flow : -0.15, MACD : 0.00, Money Flow Index : 19.70, ROC : -15.89, RSI : 41.62, STOCH (14,3) : 6.47, STOCH RSI : 0.00, UO : 30.98, Williams %R : -93.53), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Ocular Therapeutix Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (83.33 %)
4 (80.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
1 (16.67 %)
1 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.33
Strong Buy
1.40

Ocular Therapeutix Inc.

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application.

CEO: Antony C. Mattessich

Teplephone: +1 781 357-4000

Address: 15 Crosby Drive, Bedford 01730, MA, USA

Number of employees: 167

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

70%30%

Bearish Bullish

50%50%

Bearish Bullish

49%51%

News

Stocktwits